Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West, Michael McCleod, Maen Hussein et al. · The Lancet Oncology · 2019 · 1.7K citations

Medicine, Oncology, Pharmacology +12

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021 · 1.4K citations

Medicine, Oncology, Pharmacology +14

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza et al. · Journal of Clinical Oncology · 2020 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Mark A. Socinski, Makoto Nishio, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2021 · 523 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Correcting for non-compliance in randomized trials using rank preserving structural failure time models

James M. Robins, Anastasios A. Tsiatis · Communication in Statistics- Theory and Methods · 1991 · 430 citations

Public Health, Biostatistics, Epidemiologic Methods +16